XNASSNPX
Market cap4mUSD
Dec 24, Last price
3.04USD
1D
3.23%
1Q
-1.14%
IPO
-98.23%
Name
Synaptogenix Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
15.58%
Shrs. gr., 5y
14.40%
Rev. gr., 5y
%
Revenues
0k
Net income
-6m
L+10.63%
CFO
-5m
L-53.86%
Profile
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 8,320 | 16,141 | 12,623 | |||
Unusual Expense (Income) | ||||||
NOPBT | (8,320) | (16,141) | (12,623) | |||
NOPBT Margin | ||||||
Operating Taxes | (116) | (7) | ||||
Tax Rate | ||||||
NOPAT | (8,320) | (16,025) | (12,616) | |||
Net income | (6,039) 10.63% | (5,458) -56.70% | (12,604) -11.55% | |||
Dividends | (641) | (116) | ||||
Dividend yield | 20.23% | 0.06% | ||||
Proceeds from repurchase of equity | (882) | 359 | 37,134 | |||
BB yield | 27.84% | -0.18% | -3.48% | |||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | 1,253 | 1,880 | ||||
Net debt | (30,662) | (37,478) | (34,214) | |||
| Cash flow | ||||||
Cash from operating activities | (5,173) | (11,211) | (8,711) | |||
CAPEX | (3) | (7) | (3) | |||
Cash from investing activities | (2,003) | (7) | (3) | |||
Cash from financing activities | (1,641) | 14,483 | 37,133 | |||
FCF | (8,317) | (16,027) | (12,614) | |||
| Balance | ||||||
Cash | 30,100 | 37,478 | 34,214 | |||
Long term investments | 562 | |||||
Excess cash | 30,662 | 37,478 | 34,214 | |||
Stockholders' equity | (32,370) | (17,109) | (14,141) | |||
Invested Capital | 59,208 | 54,404 | 47,671 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 466 | 6,989 | 5,015 | |||
Price | 6.80 -76.56% | 29.00 -86.37% | 212.75 | |||
Market cap | 3,168 -98.44% | 202,687 -81.00% | 1,066,963 | |||
EV | (26,257) | 167,930 | 1,032,749 | |||
EBITDA | (8,314) | (16,135) | (12,618) | |||
EV/EBITDA | 3.16 | |||||
Interest | 20,671 | |||||
Interest/NOPBT | ||||||